NEOS Investment Management LLC Increases Stake in Structure Therapeutics Inc. (NASDAQ:GPCR)

NEOS Investment Management LLC increased its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 199.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 44,343 shares of the company's stock after purchasing an additional 29,542 shares during the quarter. NEOS Investment Management LLC owned 0.08% of Structure Therapeutics worth $1,203,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of GPCR. Geode Capital Management LLC grew its holdings in Structure Therapeutics by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock valued at $1,985,000 after purchasing an additional 312 shares during the last quarter. ANTIPODES PARTNERS Ltd boosted its holdings in Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after acquiring an additional 553 shares during the period. LPL Financial LLC lifted its position in shares of Structure Therapeutics by 6.0% during the fourth quarter. LPL Financial LLC now owns 11,485 shares of the company's stock worth $311,000 after purchasing an additional 646 shares during the last quarter. Money Concepts Capital Corp increased its stake in Structure Therapeutics by 4.2% in the 4th quarter. Money Concepts Capital Corp now owns 21,031 shares of the company's stock worth $570,000 after buying an additional 848 shares during the period. Finally, Assetmark Inc. grew its stake in Structure Therapeutics by 72.3% in the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after acquiring an additional 953 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Several research analysts have commented on GPCR shares. JMP Securities restated a "market outperform" rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. William Blair started coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an "outperform" rating for the company. HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Finally, Stifel Nicolaus started coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $81.29.

Structure Therapeutics Price Performance

Shares of GPCR stock traded down $0.80 during mid-day trading on Thursday, hitting $16.15. 180,019 shares of the stock traded hands, compared to its average volume of 852,705. Structure Therapeutics Inc. has a 52-week low of $15.31 and a 52-week high of $62.74. The stock has a market cap of $926.09 million, a P/E ratio of -21.82 and a beta of -2.37. The stock's fifty day moving average is $23.52 and its two-hundred day moving average is $30.73.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. As a group, equities analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.